Drug delivery systems for antihypertensive agents

Area of Science:

• Pharmaceutical Sciences
• Pharmacology
• Drug Delivery Systems

Background:

• Research in the late 1980s and early 1990s focused on sustained delivery of short-acting antihypertensives.
• Motivations included improving trough/peak ratios and extending patent life for older drugs.
• Sustained-release systems offer benefits like improved side-effect profiles and compliance.

Purpose of the Study:

• To develop novel drug delivery systems for sustained release of antihypertensive agents.
• To improve therapeutic outcomes and patient compliance with antihypertensive medications.
• To explore new delivery systems that optimize drug concentration relative to blood pressure fluctuations.

Main Methods:

• Development of novel sustained-release formulations, including alginate matrix, Geomatrix, pellet-based systems, transdermal systems, and the Gastrointestinal Therapeutic System (GITS).
• Investigation of a novel GITS variant designed to align peak drug concentration with diurnal blood pressure changes.
• Gathering data to demonstrate the efficacy of these systems in reducing cardiovascular events.

Main Results:

• Several novel drug delivery systems have already received FDA approval.
• A new GITS variant aims to optimize antihypertensive medication release around the time of greatest blood pressure change.
• Ongoing data collection is evaluating the system's potential to reduce cardiovascular mortality and morbidity.

Conclusions:

• Sustained-release antihypertensive drug delivery systems offer significant advantages over immediate-release formulations.
• Novel systems, like the optimized GITS, hold promise for improving cardiovascular outcomes.
• Further data are needed to establish the non-inferiority of these advanced delivery systems compared to established treatments.